Literature DB >> 11860348

New trends in the development of oral antidiabetic drugs.

Valeria Kecskemeti1, Zsolt Bagi, Pal Pacher, Ildiko Posa, Erzsebet Kocsis, Maria Zs Koltai.   

Abstract

A large number of oral antidiabetic agents are available today. This article provides a short review of the pharmacology and some clinical aspects of various oral antidiabetic drugs. It focuses mainly on the newest developing drugs (therapy of the near future) and on the most commonly used older groups for the common approach of every-day practice (sulphonylureas). The primary goal of this review is to compare the electrophysiological effects of glibenclamide in isolated normal and streptozotocin induced diabetic rats and alloxan induced rabbits ventricular preparations, while on the other hand to differentiate the hypoglycaemic sulphonylureas (0.1-1000 mmol/kg) according to their cardiovascular activity in healthy and diabetic animals. In vitro (1-100 micromol/l) as well as chronically treated (5 mg/kg for 10 weeks) glibenclamide prolonged the action potential duration in normal but failed to affect it in diabetic ventricular preparations. Our results suggest that the sensitivity to glibenclamide of K(ATP) channels in diabetic ventricular fibers is drastically decreased. The effects of different sulphonylureas (tolbutamide, glibenclamide, gliclazide, glimepiride) on ventricular ectopic beats as well as the duration of ventricular fibrillation induced by 10 min ischemia/50 min reperfusion in healthy and diabetic rats were compared. Tolbutamide and gliclazide dose-dependently enhanced both parameters both in healthy and diabetic groups. Glibenclamide in healthy rats increased, while in diabetic rats it decreased the arrhythmogenicity. Glimepiride depressed the arrhythmogenicity in both healthy and diabetic animals. Glimepiride proved to dose-dependently enhance the myocardial tissue flow in dog in contrast to glibenclamide. These results confirm that glimepiride has less cardiovascular actions than other sulphonylureas. From the newest oral antidiabetics this review tries to emphasize the most important basic pharmacological properties, mechanism of action, therapeutic use.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11860348     DOI: 10.2174/0929867023371427

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  4 in total

1.  Can the electrophysiological action of rosiglitazone explain its cardiac side effects?

Authors:  A Szebeni; N Szentandrássy; P Pacher; J Simkó; P P Nánási; V Kecskeméti
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Ficus deltoidea: A Potential Alternative Medicine for Diabetes Mellitus.

Authors:  Zainah Adam; Shafii Khamis; Amin Ismail; Muhajir Hamid
Journal:  Evid Based Complement Alternat Med       Date:  2012-06-03       Impact factor: 2.629

3.  Benzoxazinones as Human Peroxisome Proliferator Activated Receptor Gamma (PPARγ) Agonists: A Docking Study Using Glide.

Authors:  N Das; M Dhanawat; S K Shrivastava
Journal:  Indian J Pharm Sci       Date:  2011-03       Impact factor: 0.975

4.  Synthesis and oral hypoglycemic effect of novel thiazine containing trisubstituted benzenesulfonylurea derivatives.

Authors:  Alok Singh Thakur; Ravitas Deshmukh; Arvind Kumar Jha; P Sudhir Kumar
Journal:  Saudi Pharm J       Date:  2014-12-08       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.